Monoclonal products available for certain COVID-19 patients
(OBA®) – Montgomery, AL – Monoclonal antibody treatment for COVID-19 helps people at high risk for serious illness by building rapid immunity to the virus and preventing hospitalization, but these products are only intended for people at high risk of serious illness, individuals who have recently tested positive for COVID-19, or people who are close contacts of a person who tested positive.
The closest available site for residents of Gulf Shores, Orange Beach and Baldwin County is Mainstreet Family Care at 6280 Grelot Road in Mobile.
The US Department of Health and Human Services recently announced that monoclonal antibodies for the treatment of COVID-19 are temporarily under allocation and should be tracked by healthcare providers to ensure they are distributed where this is necessary. Not everyone qualifies for treating outpatients with monoclonal antibodies. Alabama healthcare providers have been urged to review the criteria for their administration and prioritize patients based on their risk of progression to severe COVID-19 disease.
“It is important to understand that post-exposure preventive monoclonal antibodies are not a substitute for vaccination,” said ADHD Chief Medical Officer Dr Mary McIntyre. “Prevention of any disease, including COVID-19 disease, is always best when it is an available option. The best way to prevent any infectious disease is to avoid exposure to it. People have the power to protect themselves and their families by reducing the chances of being exposed and exposing others.
The three monoclonal antibody products under emergency use authorization for the treatment of mild to moderate COVID-19 are not authorized for use in people hospitalized with COVID-19, who require oxygen therapy due to the COVID-19, children under the age of 12 the elderly, or people who need an increase in basal oxygen flow due to COVID-19 in those with other underlying conditions, no COVID-19.
Providers are strongly encouraged to consult with pediatric infectious disease specialists when considering treating children and adolescents and are encouraged to consider preventive treatment with monoclonal antibodies for people who:
- Are at high risk of developing severe COVID-19
- Have a positive COVID-19 test and have not yet been admitted to the hospital
- are 12 years of age or older and weigh at least 88 pounds
Preventive post-exposure treatment to monoclonal antibodies should be considered for people who have been exposed and who are:
- High risk of developing severe COVID-19
- 12 years of age or older and weigh at least 88 pounds
- Not fully vaccinated or vaccinated but immunocompromised or on immunosuppressive therapy
Treatment should be given as soon as possible (within 10 days) after close contact with a positive case of COVID-19, to patients who have tested positive for COVID-19 and who are at “high risk” for progression of COVID-19. disease to severe COVID -19.
High risk conditions include any of the following:
- Immunosuppressive illness or weakened immune system such as rheumatoid arthritis, lupus, cancer, or HIV
- Currently receiving immunosuppressive therapy
- Overweight (Adult – body mass index greater than 25, Child – body mass index greater than the 85th percentile for age and sex)
- Diabetes (Type 1 and Type 2)
- Cardiovascular disease / hypertension
- Chronic lung disease such as asthma or other chronic respiratory disease requiring daily medication for control
- Neurodevelopmental disorders such as cerebral palsy
- Technological dependence related to medicine (for example: tracheostomy, gastrostomy or positive pressure ventilation unrelated to COVID-19
To locate a site where monoclonal antibodies have been delivered in Alabama,
More information is available
.alabamapublichealth.gov / covid19 / prevention.html